Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002586 · ClinicalTrials.gov registry record · Phase 2
13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT00002586 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 96 participants.
The verdict
NCT00002586, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
RATIONALE: 13 Cis retinoic acid may prevent the development of cancer cells. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of 13-cis retinoic acid with or without vitamin E for chemoprevention or observation of cancer in persons at high risk of developing lung cancer.
Interventions
- DRUG 13-cis retinoic acid
- DIETARY_SUPPLEMENT Tocopherol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 1993-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002586
The ClinicalTrials.gov registry entry for NCT00002586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 13-cis retinoic acid is the first listed.
NCT00002586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002586 about?
NCT00002586 is a clinical study titled "13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer". RATIONALE: 13 Cis retinoic acid may prevent the development of cancer cells. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of 13-cis retinoic acid with or without vitamin E for chemoprevention or observation of cancer in persons at high risk of developing lung cancer.
What is the current status of trial NCT00002586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 1993-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00002586?
The interventions under investigation include: 13-cis retinoic acid (DRUG), Tocopherol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00002586?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.